Literature DB >> 350555

Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.

R C Heel, R N Brogden, T M Speight, G S Avery.   

Abstract

Disopyramide is a new antiarrhythmic drug with a pharmacological profile of action similar to that of quinidine and procainamide. In a few controlled therapeutic trails and a large number of uncontrolled studies in patients with arrhythmias, often following a myocardial infarction, disopyramide has been relatively effective (more so in ventricular than in atrial arrhythmias) and usually well tolerated. In treating premature atrial and ventricular contractions, the best-studied area of its therapeutic use, disopyramide was superior to a placebo and of similar efficacy to but better tolerated than quinidine; the drop-out rate due to adverse effects of the disopyramide group (10%) being less than one-third that of the quinidine group (36%). In an open ward setting, disopyramide used prophylactically after myocardial infarction appeared to reduce both the incidence of reinfarction and the mortality rate, while in patients treated in coronary care units although the incidence of reinfarction was lower with disopyramide than with a placebo, the mortality rate was not significantly different. Further well-designed trials with adequate numbers of patients are needed before the routine use of disopyramide in infarct patients treated in either setting can be justified. Comparative studies are also required to determine if disopyramide has advantages over other antiarrhythmic agents in this area of use. Side-effects with disopyramide are usually a result of its anticholinergic activity, a dry mouth and difficulty in urination being the most common. Like other antiarrhythmic agents, disopyramide exerts a negative inotropic action on cardiac muscle, and development of acute heart failure has been reported. Development of worsening of heart block and hypotension have also occurred. Disopyramide is largely excreted unchanged and dosage should be reduced in patients with impaired renal function, in accordance with creatinine clearance values.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350555

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

1.  Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.

Authors:  H Echizen; M Nakura; T Saotome; S Minoura; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

2.  The effects of external and internal application of disopyramide on the ionic currents of the squid giant axon.

Authors:  J R Elliott; B M Hendry
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

Review 3.  [Electrophysiological classification of newer antiarrhythmic drugs (author's transl)].

Authors:  W Schmitz
Journal:  Klin Wochenschr       Date:  1980-09-15

4.  Effect of ethanol intake on disopyramide elimination by healthy volunteers.

Authors:  H Olsen; J E Bredesen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

6.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

7.  [The effect of disopyramide of left ventricular function: an echocardiographic study of the extent and time course (author's transl)].

Authors:  C Angermann; G Autenrieth
Journal:  Klin Wochenschr       Date:  1981-07-15

Review 8.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

9.  The antiarrhythmic effects of controlled release disopyramide phosphate and long acting propranolol in patients with ventricular arrhythmias.

Authors:  P Fechter; H R Ha; F Follath; F Nager
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.

Authors:  E Lien; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.